Diversity of intratumoral regulatory T cells in B-cell non-Hodgkin lymphoma.

Autor: Spasevska I; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway., Sharma A; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway., Steen CB; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway.; Division of Oncology, Stanford University School of Medicine, Stanford, CA., Josefsson SE; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway., Blaker YN; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway., Kolstad A; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Department of Oncology, Innlandet Hospital Trust, Lillehammer, Norway.; Division of Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, Norway., Rustad EH; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway., Meyer S; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway., Isaksen K; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway., Chellappa S; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Kushekhar K; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway., Beiske K; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Division of Cancer Medicine, Department of Pathology, Oslo University Hospital, Oslo, Norway., Førsund MS; Division of Cancer Medicine, Department of Pathology, Oslo University Hospital, Oslo, Norway., Spetalen S; Division of Cancer Medicine, Department of Pathology, Oslo University Hospital, Oslo, Norway., Holte H; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Division of Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, Norway., Østenstad B; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Division of Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, Norway., Brodtkorb M; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Division of Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, Norway., Kimby E; Department of Hematology, Karolinska Institute, Stockholm, Sweden., Olweus J; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway.; Institute of Clinical Medicine, University of Oslo, Norway., Taskén K; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway., Newman AM; Division of Oncology, Stanford University School of Medicine, Stanford, CA.; Divisions of Hematology & Oncology, Department of Medicine, Stanford University, Stanford, CA., Lorenz S; Department of Core Facilities, Geonomics Core Facility, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Smeland EB; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway., Alizadeh AA; Division of Oncology, Stanford University School of Medicine, Stanford, CA.; Divisions of Hematology & Oncology, Department of Medicine, Stanford University, Stanford, CA., Huse K; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway., Myklebust JH; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway.

Publikováno v: Blood advances [Blood Adv] 2023 Dec 12; Vol. 7 (23), pp. 7216-7230.

Evaluation of CHK1 activation in vulvar squamous cell carcinoma and its potential as a therapeutic target in vitro.

Autor: Wang Z; Department of Pathology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway., Førsund MS; Department of Pathology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway., Trope CG; Department of Obstetrics and Gynecology, The Norwegian Radium Hospital, Oslo University Hospital and University of Oslo, Oslo, Norway., Nesland JM; Department of Pathology, The Norwegian Radium Hospital, Oslo University Hospital and University of Oslo, Oslo, Norway., Holm R; Department of Pathology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway., Slipicevic A; Department of Pathology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.

Publikováno v: Cancer medicine [Cancer Med] 2018 Aug; Vol. 7 (8), pp. 3955-3964. Date of Electronic Publication: 2018 Jul 02.

Patient-derived follicular lymphoma spheroids recapitulate lymph node signaling and immune profile uncovering galectin-9 as a novel immunotherapeutic target.

Autor: Dobaño-López, Cèlia, Valero, Juan García, Araujo-Ayala, Ferran, Nadeu, Ferran, Gava, Fabien, Faria, Carla, Norlund, Marine, Morin, Renaud, Bernes-Lasserre, Pascale, Arenas, Fabian, Grau, Marta, López, Cristina, López-Oreja, Irene, Serrat, Neus, Martínez-Farran, Ares, Hernández, Lluís, Playa-Albinyana, Heribert, Giménez, Rubén, Beà, Silvia, Campo, Elías

Publikováno v: Blood Cancer Journal; 5/2/2024, Vol. 14 Issue 1, p1-14, 14p

Weak SARS-CoV-2-specific responses of TIGIT-expressing CD8⁺ T cells in people living with HIV after a third dose of a SARS-CoV-2 inactivated vaccine.

Autor: Junyan Jin, Xiuwen Wang, Yongzheng Li, Xiaodong Yang, Hu Wang, Xiaoxu Han, Jin Sun, Zhenglai Ma, Junyi Duan, Guanghui Zhang, Tao Huang, Tong Zhang, Hao Wu, Xin Zhang, Bin Su

Publikováno v: Chinese Medical Journal; 12/20/2023, Vol. 136 Issue 24, p2938-2947, 10p

Weak SARS-CoV-2-specific responses of TIGIT-expressing CD8 + T cells in people living with HIV after a third dose of a SARS-CoV-2 inactivated vaccine.

Autor: Jin J; Beijing Key Laboratory for HIV/AIDS Research, Sino-French Joint Laboratory for Research on Humoral Immune Response to HIV Infection, Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China., Wang X; Beijing Key Laboratory for HIV/AIDS Research, Sino-French Joint Laboratory for Research on Humoral Immune Response to HIV Infection, Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China., Li Y; Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing 100871, China., Yang X; Beijing Key Laboratory for HIV/AIDS Research, Sino-French Joint Laboratory for Research on Humoral Immune Response to HIV Infection, Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China., Wang H; Beijing Key Laboratory for HIV/AIDS Research, Sino-French Joint Laboratory for Research on Humoral Immune Response to HIV Infection, Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China., Han X; Beijing Key Laboratory for HIV/AIDS Research, Sino-French Joint Laboratory for Research on Humoral Immune Response to HIV Infection, Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China., Sun J; Beijing Key Laboratory for HIV/AIDS Research, Sino-French Joint Laboratory for Research on Humoral Immune Response to HIV Infection, Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China., Ma Z; Beijing Key Laboratory for HIV/AIDS Research, Sino-French Joint Laboratory for Research on Humoral Immune Response to HIV Infection, Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China., Duan J; Tian Yuan Studio, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China., Zhang G; Tian Yuan Studio, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China., Huang T; Tian Yuan Studio, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China., Zhang T; Beijing Key Laboratory for HIV/AIDS Research, Sino-French Joint Laboratory for Research on Humoral Immune Response to HIV Infection, Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China., Wu H; Beijing Key Laboratory for HIV/AIDS Research, Sino-French Joint Laboratory for Research on Humoral Immune Response to HIV Infection, Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China., Zhang X; Beijing Key Laboratory for HIV/AIDS Research, Sino-French Joint Laboratory for Research on Humoral Immune Response to HIV Infection, Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China., Su B; Beijing Key Laboratory for HIV/AIDS Research, Sino-French Joint Laboratory for Research on Humoral Immune Response to HIV Infection, Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.

Publikováno v: Chinese medical journal [Chin Med J (Engl)] 2023 Dec 20; Vol. 136 (24), pp. 2938-2947. Date of Electronic Publication: 2023 Nov 14.